Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 34

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
 ended September 30, 2025, and 2024, respectively. As of September 30, 2025, there were no unrecognized stock option
expense.

The
fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model. Annually, the Company
makes predictive assumptions regarding future stock price volatility, dividend yield, expected term, and forfeiture rate. The dividend
yield assumption is based on expected annual dividend yield on a grant date. To date, no dividends on common stock have been paid by
the Company. Expected volatility for grants is based on historical volatility over a similar period as the expected term . The risk-free
interest rate is based on yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option
group. The Company uses the “simplified method” to estimate the expected term of the stock option grants. This approach is
used because the Company does not have sufficient historical exercise data to develop a reasonable estimate of expected term.

No
stock options were granted during the six months ended September 30, 2025.

     22 

Stock
option activity for the six months ended September 30, 2025 is as follows:

SCHEDULE OF STOCK OPTION ACTIVITY 

    Options Outstanding  
    Weighted- Average
                                                                                Exercise Price
                                                                                Per Share  
    Weighted- Average Remaining Contractual Life  
    Aggregate Intrinsic Value (1) 
  
    Balance at March 31, 2025 
     157,954  
     0.86  
     2.1 years  
    $- 
  
    Granted 
     -  
     -  

    Cancelled 
     -  
     -  

    Balance at September 30, 2025 
     157,954  
    $0.86  
     1.85 years  
    $37,909 

    Options exercisable at September 30, 2025 
     157,954  

    (1)
    The aggregate intrinsic
    value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $1.10 for
    the Company’s common stock on September 30, 2025 and the closing stock price of $0.60 for the Company’s common stock
    on March 31, 2025.

The